PA5-17190 targets Pyruvate Dehydrogenase in ICC, and WB applications and shows reactivity with Human, mouse, Non-human primate, and Rat samples.
The PA5-17190 immunogen is synthetic peptide corresponding to the sequences of both alpha1 and alpha2 subunits of human pyruvate dehydrogenase.
PA5-17190 detects Pyruvate Dehydrogenase which has a predicted molecular weight of approximately 43 kDa.
The pyruvate dehydrogenase (PDH) complex is a nuclear-encoded mitochondrial multienzyme complex that catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and provides the primary link between glycolysis and the tricarboxylic acid (TCA) cycle. The PDH complex is composed of multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3). The E1 enzyme is a heterotetramer of two alpha and two beta subunits. This gene encodes the E1 alpha 1 subunit containing the E1 active site, and plays a key role in the function of the PDH complex. Mutations in this gene are associated with pyruvate dehydrogenase E1-alpha deficiency and X-linked Leigh syndrome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Pyruvate Dehydrogenase Antibody (PA5-17190) in WB PA5-17190_WesternBlot.jpg
Western Blot with anti-Pyruvate Dehydrogenase Polyclonal Antibody (PA5-17190)